Pregabalin
Product Images NDC 60760-509

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pre (Pregabalin 60760 509 60)

Pre (Pregabalin 60760 509 60)
This is a description for a medication called Pregabalin, presented in capsule form and containing 300mg. The medication is packed with 60 capsules, and it was manufactured by ScieGen Pharmaceuticals in Hauppauge, NY 11788, with packaging done at St. Mary's in Oro Valley, AZ 85737. The medication is suggested to be used as directed, and the information provides an Rx number, lot number, and expiration date.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
The description is: Percent of Patients Improved: 8 8 8 8 8 3 88 8 3 o 3 v Shemmm it @ 2 2o 2 20 20 2 20 W. Percent Improvement in Pain from Baseline.*
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
The text shows a chart or table indicating the percentage of patients who improved after taking Pregabalin 160 mg three times a day for three days. There is also a measurement of improvement in pain from a baseline, which is not clearly defined. It is unclear what the numbers "2w 220 23 20 280 2 20 2w 23w" represent.*
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
The text seems to be a table showing the dosage and improvement in pain for patients taking Fregabalin, Pregataiin, and a Placebo for three times a day. The improvement percentages are shown in the last row of the table.*
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
This appears to be a table or graph with multiple rows and columns containing figures for different studies with different dosages of an unknown medication. There is a mention of "statistically significant vs. placebo." The text may not be helpful without more context or information.*
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
The text shows a graph indicating the percentage of patients who improved their pain levels after taking either a daily dose of Pregabalin at 300mg or 450mg, or a placebo. The x-axis shows the range of percentage improvement in pain from baseline, while the y-axis shows the percentage of patients who improved. There is not enough context to determine what the baseline was or the purpose of the study.*
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This appears to be a graph showing estimated percentages of subjects without LTR (not sure what that stands for) for a drug called Progabain and a placebo. The x-axis shows the number of days (up to 180), while the y-axis shows the percentage of subjects.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
This appears to be a table displaying the percentage of subjects improved after 16 weeks of a treatment, possibly involving pregabalin and a placebo. The percentages are shown on the vertical axis, starting at 100 and increasing in intervals of 10 until reaching 280. The horizontal axis displays increments of 10 from 210 to 270. There is not enough information to determine the exact nature of the subjects or the treatment being evaluated.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a formula used for calculating CLCT (Creatinine clearance) based on a patient's age, weight, and serum creatinine levels. The formula is different for female patients, as the result needs to be multiplied by 0.85. However, it is difficult to provide further information without additional context about the purpose of this calculation.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.